Neoadjuvant Weekly Nab-Paclitaxel (Abraxane) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer.

Trial Profile

Neoadjuvant Weekly Nab-Paclitaxel (Abraxane) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 May 2013 Data presented at the 2013 American Society for Clinical Oncology (ASCO) Meeting, according to a West Clinic media release.
    • 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Feb 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top